Pictorial Review of Glutamate Excitotoxicity: Fundamental Concepts for Neuroimaging

Leighton P. Mark, Robert W. Prost, John L. Ulmer, Michelle M. Smith, David L. Daniels, James M. Strottmann, W. Douglas Brown and Lotfi Hacein-Bey

AJNR Am J Neuroradiol 2001, 22 (10) 1813-1824
http://www.ajnr.org/content/22/10/1813
Pictorial Review of Glutamate Excitotoxicity: Fundamental Concepts for Neuroimaging

Leighton P. Mark, Robert W. Prost, John L. Ulmer, Michelle M. Smith, David L. Daniels, James M. Strottmann, W. Douglas Brown, and Lotfi Hacein-Bey

Neuroradiologists may encounter, on a daily basis, a challenging diversity of neurologic disorders, including stroke, trauma, epilepsy, and even neurodegenerative conditions, such as Huntington disease, AIDS dementia complex, and amyotrophic lateral sclerosis (1), but this spectrum of disease is not usually thought of as sharing the same mechanism of neuronal injury and death. These and a growing list of other neurologic disorders are now understood to share a final common destructive metabolic pathway called excitotoxicity (2, 3), which has been the focus of intense investigative efforts in the neurosciences over the past several decades (3–31). Excitotoxicity refers to an excessive activation of neuronal amino acid receptors. The specific type of excitotoxicity triggered by the amino acid glutamate is the key mechanism implicated in the mediation of neuronal death in many disorders. The discovery of excitotoxic injury is a major clue in the search for answers to such fundamental questions as why neurons die in disease states and what is the precise or critical mechanism of neuronal death.

This overview introduces and reviews some of the major concepts of glutamate excitotoxicity. Familiarity with this intriguing pathologic process will enhance the understanding of the neuroimaging changes of many neuropathologic processes, facilitate a conceptual model for some of the newer treatment strategies for some disorders (ie, stroke and trauma), and perhaps cultivate new directions for neuroimaging. The organization of this article follows the excitotoxic process from the formation of glutamate to neuronal death.

Glutamate

Glutamate is an amino acid and one of a group of amino acid neurotransmitters in the brain, although it is the principal excitatory neurotransmitter. More basically, amino acids (Fig 1) consist of a central carbon atom (α carbon) bonded to a carboxyl group (COOH) and an amino group (NH$_3$). A distinctive side chain (R group), which characterizes each amino acid, links to the α carbon. Glutamate (Fig 2) consists of the side chain CH$_2$CH$_2$COO$^-$ (COOH ending [γ carboxyl group] for glutamic acid) attached to the α carbon, while the closely related glutamine (Fig 3A and B) is created from glutamate with ammonia added at the γ carboxyl group by glutamine synthetase, forming the CH$_2$CH$_2$CONH$_2$ side chain R group. Cerebral glutamate is derived solely from endogenous sources; mainly from α ketoglutarate, which is a product of the Krebs cycle (citric acid cycle, TCA [tricarboxylic acid] cycle).

The neuronal glutamate considered here acts as a neurotransmitter, which is the method of communication between neurons. This interaction between neurons may be either excitatory or inhibitory. The major excitatory amino acid neurotransmitters are glutamate and aspartate, while GABA (γ-aminobutyric acid), glycine (aminoacetic acid), and taurine are inhibitory.

Glutamate excitotoxicity is a broad and rapidly evolving field of study with many important nuances that have necessarily been oversimplified or, unfortunately, omitted from this review for the sake of reasonable brevity. The reader is referred to the exponentially expanding literature and some of the sources listed in the reference section for additional information.
Fig 1. Amino acid. Typical amino acid consists of a central alpha carbon (Cα) that is bonded to a carboxyl group (COOH) on one side and an amino group (H₃N) on the other side. Each amino acid is characterized by a distinctive molecular group (R) or side chain attached to the α carbon.

Fig 2. Glutamate. The side chain, or R group, of glutamic acid is CH₃CH₂COOH. The carboxyl group of the side chain is designated the γ carboxyl group, which becomes fully ionized at neutral pH and is therefore frequently written with a negative charge (COO⁻). The term glutamate (instead of glutamic acid) is used to indicate this negative charge or ionized state at physiological pH.

Fig 3. A, Glutamine. This closely related amino acid is formed from glutamate with the addition of an amino group at the γ carboxyl of the side chain. B, This formation of an amide linkage at the γ carboxyl group requires the enzyme glutamine synthetase and the process is adenosine triphosphate (ATP)-dependent. This reaction is also a major mechanism for the detoxification of cerebral ammonia.

Axonal tip (Fig 5), the vesicle with the enclosed glutamate merges with the presynaptic membrane by the process called exocytosis to release the glutamate into the synaptic space between neurons. The vesicular membrane is then recycled and transported back up the neuronal axon in a retrograde fashion via the microtubular network. The synaptic glutamate is finally freed to interact with specific receptor sites on the postsynaptic membrane of the adjacent neuron to initiate an important cascade of molecular events within that neuron (Fig 6).

**Postsynaptic Anatomy**

The interaction of glutamate with the postsynaptic membrane requires a review of glutamate receptors (Fig 7). The two main types of glutamate receptors are ionotropic and metabotropic. Iontropic receptors are directly coupled to membrane ion channels. The metabotropic receptors are coupled to intermediary compounds, such as G protein, and modulate intracellular second messengers, such as inositol-1,4,5-trisphosphate (IP₃), calcium, and cyclic nucleotides. The directly coupled ionotropic
receptor, which is the primary consideration of this review, can be further subdivided into three subtypes: NMDA (\(N\)-methyl-\(D\)-aspartate), AMPA (\(\alpha\)-amino-3-hydroxy-5-methyl-4-isoxazolepropionate), and kainate. These subtypes are named for their selective chemical agonists, which resemble glutamate but do not naturally exist in the brain. This nomenclature may seem awkward, but it offers the convenience and consistency of grouping the various cerebral and cerebellar receptors according to their responses to the chemical tools that are used to evaluate or stimulate them.

Excessive accumulation of intracellular calcium is the key observed process leading to neuronal death or injury, and the NMDA receptors activate channels that allow the influx of extracellular calcium (and sodium). Overstimulation of this type of glutamate receptor would then lead to neuronal calcium overload. Some types of AMPA and kainate receptors can contribute to intracellular calcium overload because their coupled membrane ion channels are at least partially permeable to calcium.

The influx of calcium and sodium from glutamate receptor stimulation results in membrane depolarization, which can also activate voltage-dependent calcium channels. These other calcium channels then allow further calcium influx, aggravating the intracellular calcium overload initiated by overstimulation of the glutamate receptors and opening of the associated ion channels. The four main types of voltage-dependent calcium channels considered here are named for their specific properties: T (transient current), N (found in neurons), L (long duration current, large conductance channels), and P (found in Purkinje cells of the cerebellum). The L channel is not the most prevalent type but it disproportionately contributes to calcium-mediated neuronal injury because of the prolonged calcium influx that occurs with activation of this voltage-dependent conduit.

Multiple modulatory sites, however, complicate some of the ionotropic receptors. It may be helpful to think of the receptors as a receptor-channel complex with the receptor closely linked to and controlling the adjacent ion channel. Modulatory sites are separate areas on the receptor and the channel in which other molecules can influence the function of the receptor site or channel. On the NMDA receptors, glycine (once considered a laboratory con-
taminant) acts as a required coagonist. Hydrogen ions (a reflection of pH) suppress receptor activation. Polyamines, such as spermine, however, can relieve proton block and potentiate NMDA receptor activation in a pH-dependent fashion. The NMDA receptor channels are affected by multiple factors, including magnesium (which blocks the channel), zinc (positive and negative modulator), and multiple drugs, such as dizocilpine and phencyclidine ([PCP, “angel dust”] channel blocker) (Fig 8).

**Calcium**

Glutamate excitotoxic calcium overload can be appreciated from the perspective of the normal mechanisms of neuronal calcium homeostasis. Intracellular cytosolic free calcium is maintained at very low concentrations (micromolar) relative to free extracellular calcium. Plasma membrane calcium transporters regulate this cytosolic free calcium concentration. Membrane transporters in general have been classified as antiporters, symporters, and ATP-coupled active transporters (Fig 9). These transporters are membrane protein compounds that are coupled to energy sources and change the distribution of substrate ions or molecules across a membrane. Antiporters and symporters are called secondary transporters because they use the energy from an existing ion gradient to drive the passage of another ion or molecule in the same (symporter) or opposite (antiporter) direction across a membrane as the energizing ion. Movement through the neuronal mem-
Membrane channels and transporters. The ion channels are pathways to allow the diffusion of ions across the cell membrane. These channels can be opened or closed by changes in membrane voltage, associated ligands, and so on. Excessive intracellular calcium is detrimental to neuronal health, and a calcium gradient is maintained across the neuronal membrane mostly by three main types of transporters. The antiporters use an existing ion gradient (usually established by active or ATP-dependent transport) to transport calcium ions (green) in the opposite direction of the energizing ion (ie, sodium). Symporters transport calcium in the same direction of the energizing ion (blue). Both antiporter and symporters are considered secondary transporters because they derive energy from an existing gradient. The ATP-coupled active transporter is considered a primary transporter that uses ATP to affect the transmembrane movement of calcium to establish its gradient (adapted from [32]).

Calcium homeostasis. Membrane transporter (antiporter and ATP-dependent transporter) maintain a much higher extracellular calcium (small circles) concentration than the cytosol. The endoplasmic reticulum and mitochondria are important sources of intracellular extracytosolic calcium. These internal sources of calcium can be released into the cytosol when provoked by specific agents, such as the second messenger (IP$_3$) actions on the endoplasmic reticulum (adapted from [32]).

Glutamate receptor overstimulation increases intracellular calcium by directly opening ion channels and secondarily affecting calcium homeostatic mechanisms. As mentioned, the initial glutamate receptor opening of the sodium/calcium channels not only allows the influx of calcium but also causes membrane depolarization. The depolarization would in turn activate the voltage-dependent calcium channels, which would further increase the intracellular calcium levels. The decreased sodium gradient across the cell membrane caused by the glutamate receptor–coupled channels, however, would also reduce the ability of the sodium gradient–dependent antiporter to remove intracellular calcium. Superimposed disorders that decrease ATP production (ie, hypoxia, neurodegenerative disorders, etc) would adversely affect the activity of the ATP-dependent calcium transporters as well as the energy-dependent sodium potassium pump.
Fig 11. Excessive accumulation of intracellular calcium caused by overactivation of the glutamate receptor sites stimulates multiple enzymes, which are involved in normal neuronal development and function, resulting in damage to the cell membrane, cytoskeleton, and DNA.

Fig 12. Abnormally increased activation of some enzymes, such as phospholipase A, can cause an intracellular feedback cycle of events, leading to cell death.

which would then also affect the transmembrane sodium gradient and therefore the antiporter function.

Intracellular Toxic Events

The accumulation of high intracellular calcium levels triggers a cascade of membrane, cytoplasmic, and nuclear events leading to neurotoxicity. Elevation of the intracellular calcium, however, appears to be a complex issue, because inducing similar intracellular calcium levels by using a metabolic inhibitor such as cyanide or membrane depolarization with potassium causes less permanent neuronal damage than with glutamate. The glutamate-induced elevated calcium levels proceed to overactivate a number of enzymes, including protein kinase C, calcium/calmodulin-dependent protein kinase II, phospholipases, proteases, phosphatases, nitric oxide synthase, endonucleases, and ornithine decarboxylase (Fig 11). Some of these enzymes can also produce positive feedback loops to accelerate the downward spiral toward neuronal death (Fig 12). Activation of phospholipase A, for example, would generate platelet-activating factor and arachidonic acid and its metabolites. Platelet-activating factor directly contributes to the excitotoxic cascade by increasing glutamate release. Arachidonic acid inhibits reuptake of glutamate from the synaptic space, leading to further activation of glutamate receptors and more arachidonic acid formation. Increased arachidonic acid levels form oxygen free radicals, which activate phospholipase A, leading to more arachidonic acid formation. These enzymes and the generated feedback loops rapidly lead to neuronal self-digestion by protein breakdown, free radical formation, and lipid peroxidation.

Another important activated enzyme is nitric oxide synthase, which forms nitric oxide. Nitric oxide performs a variety of normal biological functions but the excessively stimulated NMDA receptors will produce abnormally increased levels of nitric oxide and superoxide ions. These substances may react and form peroxynitrite, which is extremely toxic, resulting in neuronal death. Nitric oxide can damage DNA as well as inhibit mitochondrial respiration, which in turn would create more free radicals and cause additional membrane depolarization. The nitric oxide-initiated neurotoxic cascades are important components of the mechanism of cell death in many neurodegenerative disorders, including Huntington disease (34–54).

Excessive Glutamate Accumulation

The key process that triggers the entire excitotoxic cascade is the excessive accumulation of glutamate in the synaptic space. This can be achieved by altering the normal cycling of intracranial glutamate (Fig 13) to increase the release of glutamate into the extracellular space or to decrease glutamate uptake/transport from the synaptic space, or by frank spillage of glutamate from injured neurons.
Trauma is a blunt mechanism that massively elevates the extracellular glutamate levels. Normal extracellular glutamate concentration is about 0.6 μmol/L. Substantial neuronal excitotoxic injury occurs with glutamate concentrations of 2 to 5 μmol/L. Traumatic injury to neurons can produce disastrous results with the exposure of the normal intracellular glutamate concentrations of about 10 μmol/L to the extracellular space. Mechanical injury to a single neuron, therefore, puts all of the neighboring neurons at risk. Significant collateral injury to surrounding neurons from this type of glutamate release. One recent therapeutic strategy is to immediately treat persons with injuries to the head or spinal column with glutamate receptor blockers to minimize the spread of neuronal death beyond the immediate physically disrupted neurons.
Several mechanisms of excess glutamate accumulation probably come into play in ischemia (Fig 14). Abnormal release of glutamate from its storage sites in neuronal vesicles is at least one factor. A feedback loop is generated as this released glutamate stimulates additional glutamate release. Ischemia also causes energy failure that impairs the reuptake by glutamate transporters. These transporters behave as symporters, which rely on the sodium gradient across cell membranes to move glutamate against its concentration gradients into the cell. The sodium gradient, however, is maintained by an energy-dependent pump that fails in ischemia. Such failure not only affects glutamate transport out of the synaptic space but also causes the transporters to run backward, becoming a source of extracellular glutamate rather than a sink for it. Ischemia deprives the neurons of oxygen and glucose, resulting in energy failure; however, energy failure
itself is not particularly toxic to neurons. Neural toxicity occurs with the resultant activation of the cascade of glutamate receptor–dependent mechanisms. If these receptors are blocked by appropriate antagonists, the neurons can survive a period of deprivation of oxygen and metabolic substrate. This is the rationale for the recent development and trial of glutamate receptor blockers to treat acute ischemic events (55–66). While an infarcted zone cannot be salvaged, the hope is to prevent surrounding damage to the at-risk adjacent penumbra.

These receptor blockers may also be critical in the developing arena of interventional and pharmacologically related attempts to reestablish perfusion to acutely ischemic areas of the brain. Tissue reperfusion and increased oxygen concentrations to ischemic areas without concurrent halting of the excitotoxic cascade either at the receptor or intracellular levels may increase rather than decrease neuronal damage by providing additional free radicals in the form of superoxide anions as well as by increasing the intracellular cytosol calcium levels by stimulating the release of mitochondrial calcium stores.

Acceptance of the significant role of mitochondria in neuronal death and excitotoxicity is reflected in the rapidly expanding literature on this topic during the past decade (26, 49, 67–81). Preliminary investigations into the mechanisms of mitochondrial calcium homeostasis have already inspired several therapeutic neuroprotective strategies.

A number of drugs have been developed and used in an attempt to interrupt, influence, or temporarily halt the glutamate excitotoxic cascade toward neuronal injury (82–88). One strategy is the “upstream” attempt to decrease glutamate release. This category of drugs includes riluzole, lamotrigine, and if carbon, which are sodium channel blockers. The commonly used nimodipine is a voltage-dependent channel (L-type) blocker. Attempts have also been made to affect the various sites of the coupled glutamate receptor itself. Some of these drugs include felbamate, ifenprodil, magnesium, memantine, and nitroglycerin. These “downstream” drugs attempt to influence such intracellular events as free radical formation, nitric oxide formation, proteolysis, endonuclease activity, and ICE-like protease formation (an important component in the process leading to programmed cell death, or apoptosis). Apoptosis occurs as part of the complex process of neuronal death, but many investigators believe that excitotoxicity and apoptosis are essentially different mechanisms that have intersecting influences (27, 56, 89–106).

Neuroradiologic Observations

Routine neuroimaging studies reflect the sequela of glutamate excitotoxic damage. The spreading involvement of adjacent brain tissue beyond the immediate area of insult in trauma and infarction is one example, and the delayed presentation of these conditions is another. The insidious brain parenchymal loss noted on imaging studies in patients with AIDS dementia is also thought to be related to glutamate excitotoxic injury.

The development of spectroscopy at 0.5 T has provided an intriguing opportunity to observe the combined glutamate and gluta mine (glx) peak in vivo (107). Delineation of this peak is enabled by the coalescence of the multiplets of glx at this field strength (Figs 15 and 16). The collapse of the γ and β multiplet resonances can be briefly summarized by the ratio of δ/γ (δ = chemical shift, J = spin-spin coupling constant), which governs the spectral appearance of a strongly coupled multiplet structure such as glx. The spin-spin coupling constant is determined by molecular structure and is independent of field strength, whereas the chemical shift between coupled spins is a linear function of field strength. Therefore, as the ratio of δ/γ approaches zero (or decreases), the multiplet collapses toward a single resonance line.

Interesting clinical observations are then possible and have been made with the ability to examine the glx peak. Glutamate excitotoxicity has been the implicated mechanism of neuronal injury in mesial temporal sclerosis with consistent, strong supportive experimental data (108–121). Elevated glx peaks have been observed in the hippocampi of these patients (Fig 17A and B) (122). Mitochondrial disorders, such as MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke), are functionally ischemic, although there is no hypoperfusion but rather an inability to utilize the available oxygen. Imaging findings may be variable, but spectroscopic sampling of apparently normal-appearing areas of the brain by routine imaging can reveal not only the expected lactate peaks but also an elevated glx peak (Fig 18A and B). Even neurodegenerative disorders, such as Huntington disease, have been evaluated by this technique, and elevated glx peaks have been observed in the basal ganglia (123–125).

Summary

Glutamate excitotoxicity is the final common pathway resulting in neuronal injury for many seemingly unrelated disorders, including ischemia, trauma, seizures, hypoglycemia, hypoxia, and even some neural degenerative disorders. Familiarity with this process is important for neuroradiologists because of its central position in many of the disorders encountered in daily practice. This area has been one of the most intensely investigated fields in the neurosciences over the past several decades, and the information generated from this work will clearly influence our basic understanding of many neurologic disorders.

References


Chen HS, Wang YF, Rayudu PV, et al. Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplastic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience 1998;86:1121–1132


Nicholls DG, Budd SL. Mitochondria and neuronal survival. Physiol Rev 2000;80:315–360

Dubinsky JM. Mitochondrial permeability transition (mPT) involvement in the neuronal excitotoxic pathway. In: Mark LP, ed. 2001


Gagliardi RJ. Neuroprotection, excitotoxicity and NMDA antagonists. Ang Neurosurg Psychiatry 2000;58:583–588


Adam-Vizi V. Neuroprotective effect of sodium channel blockers in ischemia: the pathomechanism of early ischemic dysfunction. Ory Hetil 2000;141:757–1286


Roy M, Saposky R. Neuronal apoptosis in acute neurologic insults: why is this subject such a mess? Trends Neurosci 1999;22:419–422


Friedlander RM, Yuan J. ICE, neuronal apoptosis and neurodegeneration [see comments]. Cell Death Differ 1998;5:823–831


Prost RW, Mark LP, Mewissen M, Li SJ. Detection of glutamate/glutamine resonances by 1H magnetic resonance spectroscopy at 0.5 tesla. Magn Reson Med 1997;37:615–618


Sutula T, Zhang P, Lynch M, Sayin U, Golara G, Rod R. Synaptic and axonal remodeling of mossy fibers in the hilus and...
116. McNamara JO. Excitatory amino acid receptors and epilepsy. Curr Opin Neurol Neurosurg 1993;6:583–587
124. Reynolds NC, Prost RW, Mark LP. Monitoring Neuroprotective Treatment of Patients at Risk for Huntington’s Disease Using Magnetic Resonance Spectroscopy at 0.5 Tesla. Presented at the 28th annual meeting of the Society for Neuroscience, Los Angeles, 1998
125. Reynolds NC, Prost RW, Mark LP. Proton Magnetic Resonance Spectroscopy in Huntington’s Disease: Indicators of Early Pathophysiologic Changes. Presented at the 6th International Congress of Parkinson’s Disease and Movement Disorders, Barcelona, 2000